大麻二酚 CBD

INT-cannabidiol-001 3 個適應症被研究
C 1 D 2

適應症與證據等級

法規與權威立場 (L4)

L4a · US FDA
立場:against
Today, the U.S. Food and Drug Administration announced that the agency has concluded that a new regulatory pathway for CBD is needed... the agency has concluded that existing regulatory frameworks for foods and supplements are not appropriate for CBD.
來源 ↗
L4b · EU EFSA
立場:against
L4c · UK NHS
立場:cautious
Healthy adults should think carefully before taking CBD, and should consider limiting their consumption of CBD from food to no more than 10mg per day, which is about 4-5 drops of 5% CBD oil. The FSA continues to advise that CBD is not taken by people in vulnerable groups, including children, people taking medication and those who are pregnant or breastfeeding and those trying to conceive.
來源 ↗
L4d · TW TFDA / 衛福部
立場:against
大麻二酚(CBD)不屬於毒品及管制藥品,考量其具有非常多藥理活性及可能的醫療用途,我國以一般藥品列管。
來源 ↗
L4e · WHO
立場:not_addressed
In general, CBD is well tolerated with a good safety profile... To date, there is no evidence of recreational use of CBD or any public health-related problems associated with the use of pure CBD. [WHO ECDD Cannabidiol (CBD) Critical Review Report, June 2018]
來源 ↗

市場與行銷 (L10)

L10a · TW Market Channels
市面上販售的 CBD 軟糖、巧克力、餅乾等都是違法販售的;CBD 在我國不得供食品原料使用
L10b · TW Legal Identity (TFDA)
倘將 CBD 供作食品用途,即違反食品安全衛生管理法第15條第1項第9款規定,得依同法第44條規定處新臺幣6萬元以上2億元以下罰鍰
L10c · TW Community (PTT/Dcard/Mobile01)
業配有用,沒業配沒用,很簡單